cjc-1295 + ipamorelin cycle length Cjc With Peptide Therapy: Ipamorelin CJC-1295 / Ipamorelin Peptide Therapy:
Description
Serious adverse events are rare but include potential insulin resistance with prolonged use beyond 4 weeks and theoretical concerns about IGF-1s mitogenic effects, though no human data confirms increased cancer risk at research doses
doi: 10.1016/j.lfs.2007.11.019
It plays a massive role in detoxification and immune health
Another common side effect associated with IGF-1 LR3 is Injection site discomfort may occur due to irritation, bruising, or inflammation at the site of injection
Nature 445:866873
Chen J, Etzel CJ, Amos CI, Zhang Q, Viscofsky N, Lindor NM, et al
